Technical Analysis for BNTC - Benitec Biopharma Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 2.69% | |
| Gapped Up | Strength | 2.69% | |
| Fell Below 20 DMA | Bearish | 2.30% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 2.30% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 2.30% | |
| Bollinger Band Squeeze | Range Contraction | 2.30% | |
| Inside Day | Range Contraction | 2.30% | |
| 20 DMA Support | Bullish | -1.75% |
| Alert | Time |
|---|---|
| Rose Above 20 DMA | 1 day ago |
| 60 Minute Opening Range Breakout | 1 day ago |
| Up 3% | 1 day ago |
| Rose Above Previous Day's High | 1 day ago |
| 20 DMA Resistance | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/11/2024
Benitec Biopharma Limited Description
Benitec Biopharma Limited, a biotechnology company, develops novel treatments for chronic and life-threatening conditions based on its gene silencing technology, DNA-directed RNA interference (ddRNAi). The company's ddRNAi technology provides novel therapeutics to treat a range of human medical diseases and conditions, such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer, and oculopharyngeal muscular dystrophy (OPMD). Its pipeline of in-house and partnered therapeutic programs include TT-034 for hepatitis C; Tribetarna for the treatment of chemotherapy resistant non-small cell lung cancer; Hepbarna for Hepatitis B; and Pabparna for the treatment of OPMD. The company also licenses its ddRNAi technology to biopharmaceutical companies for the clinical applications comprising HIV/AIDS, retinitis pigmentosa, and Huntington's disease. Benitec Biopharma Limited was founded in 1997 and is based in Sydney, Australia.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Biopharmaceutical Biology Pain Genetics Chemotherapy Small Cell Lung Cancer Hepatitis B Macular Degeneration Genetic Engineering Dystrophy Gene Expression Muscular Dystrophy Hepatitis C Wet Age Related Macular Degeneration Huntington's Disease HIV/Aids RNA Ai Technology Retinitis Rna Interference Clinical Applications Retinitis Pigmentosa Chronic And Life Threatening Conditions Gene Silencing Oculopharyngeal Muscular Dystrophy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 12.89 |
| 52 Week Low | 2.69 |
| Average Volume | 35,258 |
| 200-Day Moving Average | 7.79 |
| 50-Day Moving Average | 9.91 |
| 20-Day Moving Average | 10.70 |
| 10-Day Moving Average | 10.61 |
| Average True Range | 0.59 |
| RSI (14) | 53.27 |
| ADX | 33.64 |
| +DI | 18.68 |
| -DI | 10.88 |
| Chandelier Exit (Long, 3 ATRs) | 9.78 |
| Chandelier Exit (Short, 3 ATRs) | 11.76 |
| Upper Bollinger Bands | 11.11 |
| Lower Bollinger Band | 10.30 |
| Percent B (%b) | 0.47 |
| BandWidth | 7.55 |
| MACD Line | 0.15 |
| MACD Signal Line | 0.22 |
| MACD Histogram | -0.0723 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 11.39 | ||||
| Resistance 3 (R3) | 11.34 | 11.06 | 11.27 | ||
| Resistance 2 (R2) | 11.06 | 10.88 | 11.08 | 11.23 | |
| Resistance 1 (R1) | 10.87 | 10.77 | 10.97 | 10.92 | 11.19 |
| Pivot Point | 10.59 | 10.59 | 10.64 | 10.61 | 10.59 |
| Support 1 (S1) | 10.40 | 10.41 | 10.50 | 10.45 | 10.17 |
| Support 2 (S2) | 10.12 | 10.30 | 10.14 | 10.13 | |
| Support 3 (S3) | 9.93 | 10.12 | 10.09 | ||
| Support 4 (S4) | 9.98 |
